In a phase 3 trial, patients with prostate cancer with high-risk biochemical recurrence showed better outcomes with enzalutamide treatments vs leuprolide monotherapy with respect to metastasis-free survival. Both enzalutamide plus leuprolide and enzalutamide monotherapy significantly improved 5-year metastasis-free survival rates (87.3% and 80.0%, respectively) compared with 71.4% with leuprolide alone. The study concludes that enzalutamide, alone or with leuprolide, is superior to leuprolide alone in patients with prostate cancer and high-risk biochemical recurrence.

Reference: Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023;389(16):1453-1465. doi:10.1056/NEJMoa2303974